Candida Article #7: Saccharomyces boulardii

"I find OptiBac's Saccharomyces boulardii Saccharomyces boulardii probiotic absolutely invaluable in my practice. In my experience it is one of the best ways to support bowel health in IBS sufferers with a tendency to have cramps and diarrhoea. I also recommend it to anyone with confirmed Candida albicans overgrowth, sometimes combining it with For a flat stomach if excessive bloating is an issue. I have no hesitation to endorse OptiBac Probiotics as I trust their quality and effectiveness in clinical practice." - Miguel Toribio-Mateas, Nutritional Therapy Practitioner, London

"Following spinal surgery some years ago, like most people with this kind of problem, I found that regaining confidence in bowel control was a long and depressing process. I have also developed Type 2 Diabetes, and the medication can frequently cause upset an stomach as a well known side effect. I spoke to OptiBac, who were really helpful, and started me on Saccharomyces boulardii, taking just 2 in the morning. Within days, the whole routine became reliable and my confidence returned. I would recommend OptiBac Probiotics - in fact several friends I met whilst in hospital for my spinal surgery are already customers. " - Mark, Hampshire

"I have been suffering from very bad IBS and intestinal candida. My energy levels were zero. I read about OptiBac Probiotics and decided to try Saccharomyces boulardii. After about three days I noticed a huge improvement in my energy levels. My stomach started to feel normal again. It regulated my bowel movements, flattened my stomach and my energy levels were dramatically increased. Saccharomyces boulardii has made a marked and noticeable improvement to my symptoms, which no other probiotic has done to date. I highly recommend OptiBac Probiotics to fight IBS and Candida. " - Paola, Slough

“I took Saccharomyces boulardii during a particularly bad bout of food poisoning which involved a harrowing night of constantly rushing to the toilet. After only a couple hours of taking it, my diarrhoea had stopped completely and I felt comfortable enough to start eating properly again, plus my energy levels are on the up” - Mark, Dublin, Ireland

"I have suffered with systematic Candida for 7 years and in order to keep it at bay I take Saccharomyces boulardii daily. It's the only product I recommend to people who have an upset stomach & diarrhoea. I have had no problems nor side effects; it's a fabulous product and i shall keep using it. I know that when things seriously go wrong Saccharomyces boulardii will do its job, and naturally. The products are like the staff - exceptionally reliable, and look after my bad health." - Louisa Bray, Narborough

“I have suffered with IBS daily for 32 years and have tried every pill, potion going; nothing really worked… then I decided to try one more time with a probiotic yeast called Saccharomyces boulardii, in the product Saccharomyces boulardii. To my amazement this probiotic I can take on a daily basis… I have noticed a reduction in wind and spasms. This is a positive step in the right direction of IBS management and one I will continue with daily.” – David, Leicestershire.

“I am writing to say thank you for the previous help that you gave me last year when I contacted you about probiotics for my grandfather who was suffering from Clostridium Difficile Disease. After several courses of antibiotics had no effect, he started taking Saccharomyces boulardii capsules. After taking these for about six weeks, during another course of antibiotics, he had thrown off the bug, which, as he is 91 this year, is no mean feat!” – Emelye, East Sussex

McFarland, L.V. & Bernasconi, P. (1993) Saccharomyces boulardii: A Review of an Innovative Biotherapeutic Agent. Microbial Ecology in Health and Disease; Vol. 6 pp. 157-171.

Hochter, W. et al (1990) Saccharomyces boulardii in acute adult diarrhea. Efficacy and tolerance of treatment. Munchener Medizinische Wochenschrift; Vol. 132 (12) pp. 188-192.

Cetina-Sauri, G. & Basto, S. (1994) Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Annales de Pediatrie; Vol. 41 (6) pp. 397-400.

Kurugol, Z. & Koturoglu, G. (2005) Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Paediatrica; Vol. 94 pp. 44-47.

Maupas, J.L. et al. (1983) Treatment of Irritable Bowel Syndrome (IBS) Double Blind Trial of Saccharomyces boulardii. Medecine Chirurgie Digestives. Vol. 12 (1) pp. 77 – 79.

Kotowska, M. et al. (2005) Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Alimentary Pharmacology & Therapeutics 21 (5), 583–590

Erdeve, O. et al. (2004) 'The probiotic effect of S.boulardii in a pediatric age group' Journal of Trop Pediatr. Aug;50(4) pp.234-6

D'Souza, A. et al. (2002) Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. Care of the Elderly Section, Faculty of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London. BMJ 2002;324:1361 ( 8 June )

Kirchhelle, A. et al. (1996) Treatment of persistent diarrhoea with Saccharomyces boulardii in returning travellers. Results of a prospective study; Fortschr Med; Vol. 114 (11) pp. 136-140

Grandy, G. et al. (2010) Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children; BMC Infectious Diseases, Vol. 10 pp. 253

Ducluzeau, R. & Bensaada, M. (1982) Comparative effect of a single or continuous administration of Saccharomyces boulardii on the establishment of various strains of Candida in the digestive tract of gnotobiotic mice. Annales de microbiologie. (Inst. Pasteur). 133: pp: 491-501

Jawhara, S. & Poulain, D. (2007) Saccharomyces boulardii decreases inflammation and intestinal colonisation by Candida albicans in a mouse model of chemically-induced colitis. Medical Mycology, Vol. 45. Issue 8. pp 691 - 700.

Berg, R. et al. (1993) Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomcyes boulardii. J Infect Dis. 1993,Nov;168(5):1314-8.

Murzyn, et al. (2010) Capric Acid Secreted by S. boulardii Inhibits C. Albicans. August 2010, Plos One, Vol. 5. Issue 8.

McFarland, L.V. et al. (1994) A randomised placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. The Journal of the American Medical Association. Vol. 271. pp. 1913 - 1918

Surawicz, C.M. et al (2000) The Search for a Better Treatment for Recurrent Clostridium difficile Disease: Use of High-Dose Vancomycin Combined with Saccharomyces boulardii. Clinical Infectious Diseases. Vol. 31 pp. 1012 – 1017

Buts, J. et al. (1993) Saccharomyces boulardii for Clostridium difficile-Associated Enteropathies in Infants. Journal of Pediatric Gastroenterology and Nutrition. Vol. 16 pp. 419 – 425

Surawicz, C.M. et al. (1989) Treatment of Recurrent Clostridium difficile Colitis with Vancomycin and Saccharomyces boulardii. The American Journal of Gastroenterology. Vol. 85 (10)

Surawicz, C.M. (2003) Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans . Best Practice & Research Clinical Gastroenterology. Vol. 17 (5) pp. 775 – 783

Castagliuolo, I. et al. (1999) Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 67(I): 302 - 307.

Pothoulakis, C. et al. (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin: A binding and enterotoxicity in rat ileum. Gastroenterology: 104(4): 1108 - 1115.

Tung, J.M et al. (2010) Prevention of Clostridium difficile with Saccharomyces boulardii: A systematic review; Canadian Journal of Gastroenterology, Vol. 23(12) pp. 817-821

Guslandi, M. et al. (2000) Saccharomyces boulardii in Maintenance Treatment of Crohn's Disease. Digestive Diseases & Sciences. Vol 45, 7, 1462 - 1464.

Guslandi, M. et al. (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology & Hepatology. Vol. 15 pp. 697 – 698.